Athersys (ATHX) is a developer of regenerative medicines with its lead drug candidate, a MultiStem cell therapy, targeting ischemic stroke in a late-stage study. MultiStem has a Fast Track and RMAT (Regenerative Medicines Advanced Therapy) designation in the USA, both of which provide for expedited review. The drug has successfully gone through mid-stage studies and is now running a SPA-bound phase 3 trial. The stock has been trading sideways and down for the last 12 months, however, the upcoming data release should put some spin on the stock. We ran the stock through